Anthropic acquires a one-person biotech that used Claude to coordinate 11 labs (www.rdworldonline.com)

Anthropic has acquired Mithril Medicine, a one-person biotech firm that used its AI model, Claude, to coordinate the efforts of 11 laboratories in drug development. This acquisition is significant for the AI/ML community as it exemplifies the innovative application of AI in biotechnology, particularly in managing complex experimental logistics. Mithril's work, focused on developing therapies for two rare muscular dystrophies, marks Anthropic’s initial foray into internal drug development, following its previous acquisition of Coefficient Bio. Founder Cody Tranbarger leveraged Claude to streamline operations and expedite research, achieving mouse proof of principle for bispecific antibodies addressing LAMA2-related congenital muscular dystrophy within 18 months. The use of AI not only increased efficiency but also generated extensive documentation rapidly. While the collaboration has yielded promising results, including improved grip strength in treated mice, it has also highlighted challenges, such as errors that persisted despite human oversight. Anthropic plans to expand this "Pipeline-in-a-Person" model to other rare-disease programs, with hopes of initiating human trials as early as 2028 for its LAMA2 candidate and 2029 for another target, alpha-dystroglycanopathy, should its development progress successfully.